Page 349 - Binder2

They’ll say:

“Let’s see how regulators handle the first few approvals.”
“Let’s wait for proof-of-concept data.”
“Let’s let someone else take the clinical and regulatory
risk.”

In other words:

Do nothing now. License later—if it works.

"Between 2007 and 2017, 78% of the top-
selling drugs originated from external
innovation—yet companies that waited
until Phase 3 or later to license paid an
average of 3 to 5 times more than those
who partnered earlier."- Deloitte Center for
Health Solutions (2018)

It’s a strategy rooted in caution, not ignorance. But it’s also
a strategy that, time and again, leaves incumbents flat-
footed when true disruption finally lands.

Because by the time edible biologics have been clinically
validated, embraced by regulators, and adopted by payers,
the companies that took the risk early will have already
claimed the lead.

347